{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:23:36Z","timestamp":1761488616757},"reference-count":49,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.vaccine.2010.12.066","type":"journal-article","created":{"date-parts":[[2011,1,5]],"date-time":"2011-01-05T09:19:48Z","timestamp":1294219188000},"page":"1617-1623","source":"Crossref","is-referenced-by-count":7,"title":["Therapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: A Phase I safety study"],"prefix":"10.1016","volume":"29","author":[{"given":"Cissy","family":"Kityo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Bousheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliette","family":"Akao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Ssali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose","family":"Byaruhanga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac","family":"Ssewanyana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prossy","family":"Muloma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sula","family":"Myalo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose","family":"Magala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yichen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Mugyenyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huyen","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2010.12.066_bib0005","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0b013e31805d8ae3","article-title":"Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans: prevalence and associated factors","author":"Kiguba","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0140-6736(02)09330-3","article-title":"Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients\u2019 response, survival, and drug resistance","volume":"360","author":"Weidle","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/01.qai.0000197070.69859.f3","article-title":"Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview","volume":"41","author":"Bartlett","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0020","article-title":"Predictors of response to highly active antiretroviral therapy","volume":"16","author":"Low","year":"2006","journal-title":"AIDS Read"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0025","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/bmj.38369.669850.8F","article-title":"Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study","volume":"330","author":"Sabin","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0030","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(04)16589-6","article-title":"Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes","volume":"364","author":"Ledergerber","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0035","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/01.aids.0000183629.20041.bb","article-title":"Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides","volume":"19","author":"Dube","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0040","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1086\/496981","article-title":"The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection","volume":"41","author":"Lo","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0045","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/00126334-200104150-00006","article-title":"Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy","volume":"26","author":"Mulligan","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0050","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0140-6736(06)68857-0","article-title":"The risk of treatment versus the risk of HIV replication","volume":"367","author":"Deeks","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0055","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1136\/bmj.332.7556.1489","article-title":"Antiretroviral treatment of HIV infected adults","volume":"332","author":"Deeks","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0060","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/14712598.1.5.803","article-title":"Development of immunotherapeutic strategies for HIV-1","volume":"1","author":"Imami","year":"2001","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0065","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.1128\/JVI.73.8.6721-6728.1999","article-title":"Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy","volume":"73","author":"Kalams","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0070","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1086\/314837","article-title":"Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy","volume":"180","author":"Pontesilli","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0075","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/135965350601100104","article-title":"Long-term highly active antiretroviral therapy in chronic HIV-1 infection: evidence for reconstitution of antiviral immunity","volume":"11","author":"Jansen","year":"2006","journal-title":"Antivir Ther"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0080","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1046\/j.1365-2249.2003.02256.x","article-title":"Reconstitution of CD4+ T cell responses in HIV-1 infected individuals initiating highly active antiretroviral therapy (HAART) is associated with renewed interleukin-2 production and responsiveness","volume":"134","author":"Hardy","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0085","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1097\/00002030-200205240-00004","article-title":"HIV long-term non-progressors maintain brisk CD8 T cell responses to other viral antigens","volume":"16","author":"Valdez","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0090","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/417095a","article-title":"HIV preferentially infects HIV-specific CD4+ T cells","volume":"417","author":"Douek","year":"2002","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.vaccine.2010.12.066_bib0095","first-page":"S143","article-title":"HIV type 1-specific helper T cells: a critical host defense","volume":"14","author":"Rosenberg","year":"1998","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm806","article-title":"Therapeutic dendritic-cell vaccine for simian AIDS","volume":"9","author":"Lu","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0105","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm1147","article-title":"Therapeutic dendritic-cell vaccine for chronic HIV-1 infection","volume":"10","author":"Lu","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0110","first-page":"279","article-title":"Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients","volume":"19","author":"Levy","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0115","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1016\/j.vaccine.2005.01.010","article-title":"Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral \u201cblips\u201d","volume":"23","author":"MacGregor","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0120","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1097\/00002030-200011100-00008","article-title":"Cell-mediated immune responses to autologous virus in HIV-1-seropositive individuals after treatment with an HIV-1 immunogen","volume":"14","author":"Moss","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0125","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1073\/pnas.1131930100","article-title":"A fragment of anthrax lethal factor delivers proteins to the cytosol without requiring protective antigen","volume":"100","author":"Kushner","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0130","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1016\/j.vaccine.2005.03.022","article-title":"Modified anthrax fusion proteins deliver HIV antigens through MHC Class I and II pathways","volume":"23","author":"McEvers","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0135","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1086\/338448","article-title":"Delivery of exogenous proteins antigens to major histocompatibility complex class I pathway in cytosol","volume":"185","author":"Cao","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0140","doi-asserted-by":"crossref","first-page":"8027","DOI":"10.1073\/pnas.97.14.8027","article-title":"Free in PMC genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity","volume":"97","author":"Lu","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0145","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1089\/aid.2006.0309","article-title":"Profile of immunologic recovery in HIV-infected Ugandan adults after antiretroviral therapy","volume":"23","author":"Baker","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0150","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1089\/aid.2009.0015","article-title":"Influence of a vaccination schedule on viral load rebound and immune responses in successfully treated HIV-infected patients","volume":"25","author":"Castro","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0155","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00126334-200212010-00001","article-title":"Modeling the effects of vaccination on chronically infected HIV-positive patients","volume":"31","author":"Jones","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0160","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1056\/NEJM199605093341903","article-title":"Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1","volume":"334","author":"Stanley","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0165","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.4049\/jimmunol.179.3.1979","article-title":"Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction","volume":"179","author":"D'Souza","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0170","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0175","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/COH.0b013e3282f9ae8b","article-title":"Programmed death-1 as a factor in immune exhaustion and activation in HIV infection","volume":"3","author":"Kaufmann","year":"2008","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0180","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1128\/JVI.77.3.2081-2092.2003","article-title":"Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load","volume":"77","author":"Addo","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0185","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1128\/JVI.78.2.630-641.2004","article-title":"Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection","volume":"78","author":"Draenert","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0190","doi-asserted-by":"crossref","first-page":"11983","DOI":"10.1128\/JVI.75.24.11983-11991.2001","article-title":"Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection","volume":"75","author":"Betts","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0195","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ni845","article-title":"HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors","volume":"3","author":"Migueles","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0200","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1126\/science.277.5322.112","article-title":"Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease","volume":"277","author":"Autran","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0205","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.aids.0000206504.09159.d3","article-title":"Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals","volume":"20","author":"Levy","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0210","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1097\/00002030-200305230-00002","article-title":"Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization","volume":"17","author":"Robbins","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0215","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1089\/088922200308954","article-title":"Enhancement of HIV type 1 antigen-specific CD4+ T cell memory in subjects with chronic HIV type 1 infection receiving an HIV type 1 immunogen","volume":"16","author":"Maino","year":"2000","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0220","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/infdis\/173.6.1336","article-title":"A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400\/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137)","volume":"173","author":"Valentine","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0225","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1001\/jama.284.2.183","article-title":"Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: a randomized controlled trial","volume":"284","author":"Davey","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0230","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1097\/00002030-200309260-00002","article-title":"Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection","volume":"17","author":"Lange","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0235","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1476-8518-5-6","article-title":"A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy","volume":"5","author":"Hardy","year":"2007","journal-title":"J Immune Based Ther Vaccines"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0240","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.4049\/jimmunol.0803771","article-title":"PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention","volume":"182","author":"Kaufmann","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2010.12.066_bib0245","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1182\/blood-2006-09-044826","article-title":"PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors","volume":"109","author":"Zhang","year":"2007","journal-title":"Blood"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10018396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10018396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T19:04:43Z","timestamp":1685905483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10018396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S0264410X10018396"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.12.066","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}